348 related articles for article (PubMed ID: 35004336)
1. TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study.
Yang B; Jie L; Yang T; Chen M; Gao Y; Zhang T; Zhang Y; Wu H; Liao Z
Front Oncol; 2021; 11():821599. PubMed ID: 35004336
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
3. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.
Chen R; Li Y; Song K; Li L; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Apr; 13(2):780-786. PubMed ID: 35557575
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
Lin LW; Yan LY; Ke K; Yang WZ; Lin JQ; Huang N
Brachytherapy; 2023; 22(6):858-871. PubMed ID: 37574351
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Zou X; Xu Q; You R; Yin G
Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
[TBL] [Abstract][Full Text] [Related]
7. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis.
Chu HH; Kim JH; Shim JH; Yoon SM; Kim PH; Alrashidi I
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365655
[TBL] [Abstract][Full Text] [Related]
8. Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Xia WL; Zhao XH; Guo Y; Hu HT; Cao GS; Li Z; Fan WJ; Xu SJ; Li HL
Clin Transl Gastroenterol; 2023 May; 14(5):e00581. PubMed ID: 36920551
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation.
Zhou Q; An Y; Liu T; Liu Z; Li R; Wang C; Zhou F; Liu C; Zhu K
Int J Hyperthermia; 2022; 39(1):97-107. PubMed ID: 34979845
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.
Sun L; Xu X; Meng F; Liu Q; Wang H; Li X; Li G; Chen F
Front Oncol; 2022; 12():980214. PubMed ID: 36249023
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.
Deng J; Liao Z; Gao J
Curr Oncol; 2023 Jan; 30(1):1243-1254. PubMed ID: 36661745
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
Zhang X; Wang K; Wang M; Yang G; Ye X; Wu M; Cheng S
Oncotarget; 2017 Apr; 8(17):29416-29427. PubMed ID: 28177886
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
14. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Moriguchi M; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Ogasawara S; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y
Liver Cancer; 2022 Jul; 11(4):354-367. PubMed ID: 35978604
[TBL] [Abstract][Full Text] [Related]
15. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
[TBL] [Abstract][Full Text] [Related]
16. Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis.
Zhang ZH; Hou SN; Yu JZ; Zhang W; Ma JQ; Yang MJ; Liu QX; Liu LX; Luo JJ; Qu XD; Yan ZP
Front Oncol; 2022; 12():1086095. PubMed ID: 36741718
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial.
Guo L; Wei X; Feng S; Zhai J; Guo W; Shi J; Lau WY; Meng Y; Cheng S
Hepatol Int; 2022 Dec; 16(6):1368-1378. PubMed ID: 36271176
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
Lin Z; Chen D; Hu X; Huang D; Chen Y; Zhang J; Li X; Zou X
Am J Cancer Res; 2023; 13(11):5455-5465. PubMed ID: 38058801
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Treated With Transarterial Chemoembolization and Sorafenib
Hu HT; Luo JP; Cao GS; Li Z; Jiang M; Guo CY; Yuan H; Yao QJ; Geng X; Park JH; Cheng HT; Jiang L; Ma JL; Zhao Y; Li HL
Front Oncol; 2021; 11():806907. PubMed ID: 35004330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
